	US 12,285,008 B2
	Methods to improve organ viability
Jim Potenziano, Hazelwood, MO (US)
Assigned to MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED, Dublin (IE)
Filed by Mallinckrodt Pharmaceuticals Ireland Limited, Dublin (IE)
Filed on Jan. 10, 2024, as Appl. No. 18/409,181.
Application 18/409,181 is a continuation of application No. 17/360,916, filed on Jun. 28, 2021, granted, now 11,950,590.
Application 17/360,916 is a continuation of application No. 16/112,297, filed on Aug. 24, 2018, granted, now 11,044,904, issued on Jun. 9, 2021.
Claims priority of provisional application 62/550,463, filed on Aug. 25, 2017.
Prior Publication US 2024/0138399 A1, May 2, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A01N 1/02 (2006.01); A61B 17/00 (2006.01)

CPC A01N 1/021 (2013.01) [A01N 1/0226 (2013.01); A01N 1/0247 (2013.01); A61B 17/00 (2013.01); A61B 2017/00969 (2013.01)]

27 Claims

1. A method for increasing superoxide dismutase 2 (SOD2 or manganese-dependent superoxide dismutase (MnSOD)) activity in an organ with ischemia-reperfusion damage, the method comprising:

continuously administering a composition comprising 20 ppm or less of NO gas directly to the organ, wherein MnSOD activity is increased in the organ compared to a control organ that has not been contacted with the composition.